Making decisions about hormone replacement therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2008
   Pooled it
2. GPR30-mediated NETs degradation via Trex1 in heart failure of aged female mice.Journal of translational medicine · 2026
   Article
3. Estrogenic activity and toxicity screening of Damnacanthal nanospheres and their metabolites assessed using anToxicology reports · 2022
   Article
4. Royal Jelly-A Traditional and Natural Remedy for Postmenopausal Symptoms and Aging-Related Pathologies.Molecules (Basel, Switzerland) · 2020
   Review
5. Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rats [corrected].American journal of translational research · 2017
   Article
6. The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan.International journal of environmental research and public health · 2016
   Article
7. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.Oncotarget · 2015
   Article
8. Cyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivo.PloS one · 2013
   Article
9. Naringenin: a partial agonist on estrogen receptor in T47D-KBluc breast cancer cells.International journal of clinical and experimental medicine · 2013
   Article
10. Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women.Medical science monitor : international medical journal of experimental and clinical research · 2011
    Article
11. A randomised controlled trial of cognitive-behavioural therapy for women with problematic menopausal hot flushes: MENOS 2 trial protocol.BMJ open · 2011
    Article
12. Phytoestrogens in postmenopausal indications: A theoretical perspective.Pharmacognosy reviews · 2011
    Article
13. Estrogenic activities of Fatty acids and a sterol isolated from royal jelly.Evidence-based complementary and alternative medicine : eCAM · 2008
    Article
14. Hormonal treatment, mild cognitive impairment and Alzheimer's disease.International psychogeriatrics · 2008
    Review
15. Effect of clinical trial publicity on HRT prescribing in Ireland.European journal of clinical pharmacology · 2006
    Article
16. What are the chances? Evaluating risk and benefit information in consumer health materials.Journal of the Medical Library Association : JMLA · 2004
    Review
17. Benefits and harms associated with hormone replacement therapy: clinical decision analysis.BMJ (Clinical research ed.) · 2004
    Article
18. Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.Drugs · 2004
    Review
19. Making decisions about hormone replacement therapy: preparations containing oestrogen should not be given during treatment for breast cancer.BMJ (Clinical research ed.) · 2003
    Article
20. Making decisions about hormone replacement therapy: bisphosphonates should not be recommended for women aged 50.BMJ (Clinical research ed.) · 2003
    Article

Corrections and comments

• Commented on by
  Making decisions about hormone replacement therapy: bisphosphonates should not be recommended for women aged 50.2003
• Commented on by
  Making decisions about hormone replacement therapy: preparations containing oestrogen should not be given during treatment for breast cancer.2003

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as